LAG3 and non-small cell lung carcinoma: LAG-3-Ig fusion protein eftilagimod alpha plus pembrolizumab caused an overall response rate (ORR) of 33% and 50% in pembrolizumab-refractory and anti-PD-1 naïve non-small cell lung cancer (NSCLC) patients, respectively,53 and showed a similarly considerable effect54 in head and neck squamous cell carcinoma (HNSCC) patients, thus was granted fast track status by FDA for NSCLC and HNSCC.